代謝性疾病治療藥的全球市場:2020-2027年

全球代謝性疾病治療藥的市場，由於代謝性疾病的盛行率上升，代謝性疾病研究的資金提供及政府支援，個人化醫療的研究，代謝體學生物標記的研究，先進的分析工具的開發等要素而受到推動。

本報告提供全球代謝性疾病治療藥的市場調查，市場及產品概要，新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析，法律規章、償付環境，未滿足需求，專利趨勢，市場規模的變化、預測，技術、疾病區分、用途、地區/主要國家等各種區分的明細，競爭環境與市場佔有率，主要企業簡介等資料彙整。

第1章 調查手法、調查範圍

第2章 市場定義和概要

第3章 摘要整理

第4章 市場動態

• 市場影響因素
  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析

第5章 產業分析

• 波特的五力分析
• 供應鏈分析
• 價值鏈分析
• PEST分析
• 價格分析
• 法規分析
• 償付分析
• 未滿足需求
• 專利趨勢

第6章 COVID-19:影響分析

第7章 市場分析、預測:各技術

• 市場規模分析、與前一年同期比較成長率
• 市場魅力指數
• 分離工具
• 高效液相層析
• 生物資訊學工具、資料庫、服務
• 其他

第8章 市場分析、預測:各疾病種類

• 市場規模分析、與前一年同期比較成長率
• 市場魅力指數
• 癌症
• 心血管疾病
• 神經疾病
• 其他

第9章 市場分析、預測:各用途

• 市場規模分析、與前一年同期比較成長率
• 市場魅力指數
• 生物標記、藥物研發
• 毒物學
• 營養基因學
• 個人化醫療
• 其他

第10章 市場分析、預測:各地區、主要國家

• 市場規模分析、與前一年同期比較成長率
• 市場魅力指數
• 北美
• 歐洲
• 南美
• 亞太地區
• 中東、非洲

第11章 競爭情形

• 競爭模式
• 市場地位、佔有率分析
• M&A分析

第12章 企業簡介

• AB Sciex Pte. Ltd.
• Agilent Technologies
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• GE Healthcare
• Human Metabolome Technologies, Inc.
• LECO Corporation
• Merck KGaA
• Metabolon, Inc.
• Hua Medicine
• 3SBio Group
• Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
• Innovent Biologics
• Huadong Medicine Co., Ltd.

第13章 重要考察

第14章 關於附錄、本公司

Global Metabolism Drugs Market is segmented By Technology (Separation Tools, High-Performance Liquid Chromatography, Bioinformatic Tools, Databases & Services, Others), By Method (Cancer, Cardiovascular Diseases, Neurological Diseases, Others), By Application (Biomarker and Drug Discovery, Toxicology, Nutrigenomics, Personalized Medicines, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Metabolism Drugs Market is expected to grow at a CAGR of 8.54% during the forecasting period (2020-2027).

Metabolism drugs are used to treat metabolic diseases that occur due to a stockpile of proteins, urea, lipids, glycogen, calcium stones, and toxic substances. The improper functioning of metabolism can lead to various metabolic disorders, such as hereditary tyrosinemia, Gaucher disease, Fabry disease, and hereditary orotic aciduria.   

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The rising prevalence of metabolic diseases and the government's support through funding for the study of metabolic disorders are some factors that are expected to propel market growth. Moreover, the research in personalized medicine and the continuous development of advanced analytical tools are further supporting the growth of the market across the globe.

Research in metabolomics biomarkers will continue supporting the growth of the market during the forecast period.

Research conducted by different research institutes and universities has turned to proteomics for developing new biomarkers. The latest research has improved the biomarkers' accuracy as early diagnosis of the diseases enables better treatment. Presently, scientists are focusing on the metabolites for detecting the results of the therapy process. In December 2018, the Municipal Institute for Medical Research started a clinical study by collaborating with the University of Barcelona to study novel predictive biomarkers. Moreover, the University of Leicester started the clinical trial in February 2017 for exhaled breath metabolomic biomarkers in acutely breathless patients. These trials provide new case studies coupled with new developments in the metabolomics biomarker that enable the biomarker's adoption in the disease diagnosis and drug discovery that propel the market growth.

Continuous developments in analytical tools are driving the growth of the global market.

Mass spectrometry development coupled with chromatography has advanced the reliability and efficiency of metabolomic profiling and shows the key structures in medical fields. The bio-information provided by these technologies enables accurate disease diagnostics and the useful clinical ability to manage diseases at the metabolomic level in absorption. The benefits of high sensitivity, highly accurate, and high throughput metabolomics show substantial capability in disease treatment.

COVID-19 Impact Analysis

The COVID-19 pandemic has impacted the growth of the metabolism drugs market. The sales of mass spectrometry, chromatography instruments, and other metabolism research instruments have modestly declined, as the prime focus of the research institutes and pharmaceutical companies have diverted to the development of the COVID-19 vaccine. Therefore, the metabolism drugs market is expected to foresee a considerable decline in 2020.

Segment Analysis

Based on the technology, the metabolism drugs market has been classified into separation tools, high-performance liquid chromatography, bioinformatics tools, databases & services, and others.

The high-performance liquid chromatography segment accounted for the highest market share in the global market.

Mass spectrometer and liquid chromatography have evolved into a crucial technology for the field of metabolism drugs. It is used to diagnose colorectal cancer, oral cancer, and hepatocellular carcinoma. Hence, this is established as a new and potential diagnostic approach. The introduction of automated chromatography instruments is expected further to propel the market growth during the forecast period.

Based on the application, the metabolism drugs market has been classified into biomarker and drug discovery, toxicology, nutrigenomics, personalized medicine, etc.

Biomarker and drug discovery segment dominated the global metabolism drugs market in 2019

There is extensive use of metabolism drugs to apply metabolomics biomarker and drug discovery to cure chronic diseases such as cancer, neurological disorders, CVDs, etc. Moreover, many small and medium pharmaceutical companies are emerging in the market, intending to develop metabolomics biomarkers to diagnose chronic diseases, fueling the segment's growth over the forecast period. Therefore, it contributes a major share in the growth of the metabolism drugs market across the globe.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Based on geography, the study analyzes the global market's metabolism drugs market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America leads the global market throughout the forecast period.

North America dominated the global metabolism drugs market and expected to retain its position during the forecast period. The US contributed over 82.0% to the North American metabolism drugs market in 2019. The region's growth is due to a well-developed healthcare infrastructure and many healthcare research institutes across the region. Moreover, increasing funding in the field of metabolomics is also augmenting the market across the region.

The Asia Pacific is estimated to grow at a considerable growth rate in the metabolism drugs market during the forecast period. Governments of various economies of the region are making efforts for the establishment of R&D centers by foreign-affiliated companies to enhance the metabolism drugs market scenario across the region. Moreover, the rising prevalence of chronic diseases such as cancer and CVDs are fueling the demand for novel diagnostic technologies and methods, such as metabolomics biomarkers, for their treatment.

Metabolism Drugs Market Competitive Landscape

The metabolism drugs market is highly competitive. The key metabolism drug players contributing to the global market's growth include Agilent Technologies, Bruker Corporation, GE Healthcare, Merck KGaA, Hua Medicine, 3SBio Group, Shanghai Fosun Pharmaceutical(Group)Co., Ltd., and Innovent Biologics. The major players are adopting new product launch and expansion strategies for global growth in the metabolism drugs market.   

Agilent Technologies, Inc.

Overview: Agilent Technologies, Inc. was established in 1999 and is headquartered in Santa Clara, California. The company operates in three segments, including life sciences and applied markets, diagnostics and genomics, and Agilent Cross Lab. The company offers various systems, including liquid chromatography-mass spectrometry systems, gas chromatography systems, gas chromatography-mass spectrometry frameworks, and inductively coupled plasma mass spectrometry instruments, nuclear ingestion instruments, and others. The Agilent CrossLab portion offers GC and LC segments, test planning products, custom sciences, different research facility instrument supplies, resource administration, and meeting administrations. The company sells the product through direct deals, online websites, affiliates, distributors, and merchants. It has a joint venture with the University of Southern California Michelson Center for Convergent Bioscience.

Product Portfolio: The company provides workflows for discovery and targeted metabolomics analysis by CE/MS, GC/MS, LC/MS, and SFC/MS. These workflows are devised for the company's mass spectrometry product portfolio, including single quadrupole, triple quadrupole, quadrupole time-of-flight, and time-of-flight mass analyzers. The company also offers advanced analysis software for processing, identifying, and interpreting complex metabolomics data.

 Recent Development: In February 2019, Agilent Technologies, Inc. launched two new gas chromatography systems integrating innovative and intelligent 'self-aware' predictive technology.

Why Purchase the Report?

Visualize the metabolism drugs market segmentation composition by technology, method, application, and region, highlighting the critical commercial assets and players.

Identify commercial opportunities in the metabolism drugs market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of metabolism drugs market - level 3 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global metabolism drugs market report would provide access to an approx: 70 market data table, 62 figures, and 274 pages.

Target Audience

Industry Investors

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Related Topic's

AMD Drugs Market

Generic Drugs Market

Orphan Drugs Market

Table of Contents

Table of Contents

Global Metabolism Drugs Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Global Metabolism Drugs Market - Market Definition and Overview

Global Metabolism Drugs Market - Executive Summary

Market Snippet by Technology

Market Snippet by Method

Market Snippet by Application

Market Snippet by Region

Global Metabolism Drugs Market-Market Dynamics

Market Impacting Factors

Drivers

Availability of government funding for metabolic research

Increase in spending for the development of personalized medicine

Restraints:

The high cost of tools and instruments  

Opportunity

Impact Analysis

Global Metabolism Drugs Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Value Chain Analysis

PEST Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Patent Trends

Global Metabolism Drugs Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Global Metabolism Drugs Market - By Technology

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment

Market Attractiveness Index, By Technology Segment

Separation Tools*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

High-Performance Liquid Chromatography

Bioinformatic Tools, Databases & Services

Others

Global Metabolism Drugs Market - By Method

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method Segment

Market Attractiveness Index, By Method Segment

Cancer*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Cardiovascular Diseases

Neurological Diseases

Others

Global Metabolism Drugs Market - By Application

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment

Market Attractiveness Index, By Application Segment

Biomarker and Drug Discovery*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Toxicology

Nutrigenomics

Personalized Medicines

Others

Global Metabolism Drugs Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

The U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

The U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

The Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Method

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Global Metabolism Drugs Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Global Metabolism Drugs Market- Company Profiles

AB Sciex Pte. Ltd.*

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

Agilent Technologies

Beckman Coulter, Inc.

Bio-Rad Laboratories, Inc.

Bruker Corporation

GE Healthcare

Human Metabolome Technologies, Inc.

LECO Corporation

Merck KGaA

Metabolon, Inc.

Hua Medicine

3SBio Group

Shanghai Fosun Pharmaceutical(Group)Co., Ltd.

Innovent Biologics

Huadong Medicine Co., Ltd.

Global Metabolism Drugs Market - Premium Insights

Global Metabolism Drugs Market - DataM Intelligence

Appendix

About Us and Services

Contact Us

Suggestions for Related Market Report:

Global Metabolic Testing Market

Global Human Microbiome Market

Global Metabolomics Biomarker Market

Global Clinical Chemistry Analyzer Market